BioDelivery Sciences (NASDAQ:BDSI) shareholders got some welcome good news today, with positive phase 3 top-line data for BEMA buprenorphine sending shares up 9% as of this writing.
The drug provided a statistically significant improvment in chronic pain relief versus placebo, and the trial's completion triggered a $10 million payment from commercialization partner Endo International (NASDAQ:ENDP). So, considering today's good news, should investors think about buying BioDelivery stock?
In the video below, Motley Fool health care analysts Michael Douglass and David Williamson give more details on the drug and whether this makes BioDelivery Sciences a stock to buy.
Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.
David Williamson has no position in any stocks mentioned. Michael Douglass has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.